GlassScriptPhysician profile
Erik D Bernstein
NPI 1174562235
$3,172.56
in general payments reported to CMS, 2019-2025
28 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $77.37 · 2021: $140 · 2022: $423 · 2023: $443 · 2024: $569 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811 · Education: $4.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.59 |
| Education | $4.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $426.39 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $344.48 | 2019-2025 | Jynarque |
| Amgen INC. | $273.13 | 2019-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $257.54 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $202.98 | 2023-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $171.02 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $153.25 | 2019-2025 | Rayaldee |
| Ardelyx, INC. | $126.16 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $125.96 | 2019-2025 | Filspari |
| Averitas Pharma INC. | $111.91 | 2024-2025 | Qutenza |
| Aurinia Pharma U.S., INC. | $109.07 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $93.25 | 2021-2025 | Shingrix |
| Horizon Therapeutics Plc | $92.83 | 2022-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $85.82 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $80.71 | 2020-2025 | Velphoro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.24 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $58.70 | 2022 | |
| Shire North American Group INC | $52.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $51.30 | 2023-2024 | Ultomiris |
| Cormedix INC. | $49.63 | 2024-2025 | Defencath, Defencath |
| Novartis Pharmaceuticals Corporation | $44.62 | 2024-2025 | |
| Daiichi Sankyo INC. | $39.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.27 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $35.55 | 2019 | |
| Cvrx, INC. | $25.68 | 2025 | Barostim Neo System |
| Mallinckrodt Enterprises LLC | $25.50 | 2019 | |
| Akebia Therapeutics INC | $24.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.